Current and future medical treatments for patients with acromegaly.

about

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.

P2860

Q37718173-333E5EFF-5D1F-42FD-A656-35DD6D59924F Q42361469-4F148E27-6F57-4DDC-9DF4-1CF3293DF561

P2860

Current and future medical treatments for patients with acromegaly.

Item

http://www.wikidata.org/entity/Q38847622

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Current and future medical treatments for patients with acromegaly.

@en

type

Item

label

Current and future medical treatments for patients with acromegaly.

@en

prefLabel

Current and future medical treatments for patients with acromegaly.

@en

P1476

Current and future medical treatments for patients with acromegaly

@en

P2093

Andrea Giustina

http://www.w3.org/2001/XMLSchema#string

Anna Maria Formenti

http://www.w3.org/2001/XMLSchema#string

Filippo Maffezzoni

http://www.w3.org/2001/XMLSchema#string

Stefano Frara

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of acidification and apoptosis by SHP-1 and Bcl-2

Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway

Somatostatin and its receptor family

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin

Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

P304

1631-1642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2016.1199687

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gherardo Mazziotti

P577

2016-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27352098

http://www.w3.org/2001/XMLSchema#string

Current and future medical treatments for patients with acromegaly.

about

P2860

P2860

Current and future medical treatments for patients with acromegaly.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698